Background-Insight into type 6 long-QT syndrome (LQT6), stemming from mutations in the KCNE2-encoded voltagegated channel β-subunit, is limited. We sought to further characterize its clinical phenotype. 
L ong-QT syndrome (LQTS) is an inherited arrhythmia syndrome associated with an increased risk of sudden cardiac death secondary to torsades de pointes (TdP). 1 To date, 16 different LQTS-susceptibility genes have been identified, and many of the genetic subtypes possess unique phenotypic features.
2 Type 6 long-QT syndrome (LQT6), estimated to have an overall prevalence of ≈0.0005%, has been attributed to mutations within KCNE2, a gene that encodes an accessory or β-subunit that modulates the activity of multiple different voltage-gated ion channels ( Figure 1 ). 3 Contrasting with its low prevalence, many KCNE2 variants implicated in LQT6 have higher than anticipated frequencies within populationbased exome cohorts. 4 It is also notable that reported LQT6 cases have almost invariably had normal baseline QT intervals and only experienced arrhythmic events in the setting of an additional QT-prolonging insult. [5] [6] [7] In contrast with the Mendelian inheritance patterns often observed with canonical forms of LQTS, familial genotype-phenotype segregation has never been previously documented for a KCNE2 mutation and an LQTS phenotype, potentially reflecting a need for secondary provocation. Consistent with this theme, in the seminal Do KCNE2 Mutations Cause LQTS? study implicating KCNE2 in LQTS, the authors concluded: "A mechanism for acquired arrhythmia is revealed: genetically based reduction in potassium currents that remains clinically silent until combined with additional stressors". 5 Although highlighted in initial reports, the notion that KCNE2 is an arrhythmia-susceptibility, rather than disease-causing gene seems largely unappreciated, as highlighted by contemporary reviews and textbooks listing KCNE2 as a cause of canonical LQTS. 8, 9 Such misclassification, assuming that initial reports were accurate, has the potential to lead to widespread inappropriate clinical care, particularly given the emergence of large-scale exome sequencing initiatives within healthcare systems. 10 We sought to further clarify the alleged LQT6 phenotype through a novel case series composed of individuals identified to possess reported pathogenic KCNE2 mutations during clinical evaluation and a systematic review of previous literature reported cases.
Methods

Novel Case Series
Inherited arrhythmia clinics and the Rochester LQTS registry provided details on individuals evaluated for arrhythmic disorders possessing possible or presumed pathogenic KCNE2 mutations. 11 The following variables were recorded for each case: age at presentation, sex, Bazett-corrected QT interval (QTc), family history of LQTS or sudden cardiac death, history of a cardiac event and any potential secondary stressors, panel of genes screened, the presumed KCNE2 culprit mutation, and presence of other potentially pathogenic mutations relevant to cardiac arrhythmias. Whenever possible, evidence for genotype-phenotype segregation was sought. When available, treadmill testing (QTc supine, on standing, at peak exertion, and at 4 minutes into recovery) and cardiac imaging data were collected. Study participants were also assessed for sinus node dysfunction and other arrhythmic features (details provided in the Data Supplement). The study was performed as part of a protocol approved by the research ethics boards of Western University, London, Ontario, Canada, and the collaborating institutions. Study participants provided informed consent.
Systematic Literature Review of Reported Cases
The MEDLINE electronic database was searched for articles in the English language published before November 2016 using the medical subject headings KCNE2 and long QT. Identified articles were reviewed for reported cases of LQTS attributed to KCNE2 mutations. Published cases were eligible for inclusion if the clinical context of the diagnosis and cardiac event were provided. Cases reported as part of genetic compendiums of LQTS in the absence of clinical details were excluded.
Evaluation of Reported Pathogenic KCNE2 Mutations
All KCNE2 mutations implicated in LQT6, including those reported in ClinVar (a public archive of genetic variants and associated diseases), 12 were subjected to in silico analyses and variant classification according to current American College of Medical Genetics guidelines. 13 Their prevalence within the general population was assessed using the Exome Aggregation Consortium (ExAC), a database comprised 60 706 nonrelated individuals derived from multiple population-based and disease-specific genetic cohort studies. 4 In silico prediction was performed using Polymorphism Phenotyping v2, 14 Sorting Intolerant From Tolerant, 15 and Mutation Taster. 16 The literature was also reviewed for previous in vitro functional analyses.
Results
Phenotype of Subjects With Reported Pathogenic
KCNE2 Mutations
Among 15 inherited arrhythmia clinics and the Rochester LQTS Registry, we identified 48 individuals from 28 families possessing a rare KCNE2 variant classified as likely pathogenic or pathogenic. All probands were at minimum screened for mutations in KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 (Table I in the Data Supplement) . Thirty-two of the 48 study participants had undergone cardiac imaging, and, aside from 2 individuals, all those possessing KCNE2 variants had normal biventricular size and function (Table II in the  Data Supplement) . Importantly, in no instance did the variant segregate with a phenotype consistent with LQTS (Table 1) . The probands from 7 families (Table 1; Figure 2 ) had a normal resting QTc and another predisposing factor for QT prolongation at the time of their cardiac event or diagnosis.
Among the 13 probands with a typical LQTS phenotype, 9 possessed a pathogenic mutation in another LQTS gene (Table 1; Figure 2 ). In family 8, the proband that suffered a cardiac arrest had a prolonged QTc; however, genetic testing was negative. Subsequent screening of family members identified a daughter with a QTc of 464 ms who had a KCNE2-Asn6Ser variant that was absent from the cardiac arrest victim. The remaining probands with an LQTS phenotype were from Families 26 (Thr10Met), 27 (Ile57Thr), and 28 (Glu94Gly). Notably, all of the first-degree family members that had these KCNE2 variants exhibited a normal QT phenotype (Table 1) .
Among the remaining 8 probands (Table 1 ; Figure 2 ) possessing a KCNE2 mutation, none had an LQTS phenotype on baseline ECG. Three of these 8 probands were evaluated with treadmill testing, and all exhibited normal QT behavior on standing from lying (Table III in the Data Supplement). The proband in family 25 exhibited mild QT prolongation during peak exercise and at 4 minutes in recovery (QTc values=479 and 476, respectively), although this was in the presence of right bundle branch block. His 3 children possessing
WHAT IS KNOWN
• Mutations within the KCNE2-encoded voltage-gated channel β-subunit have been implicated as causative for LQT6 (type 6 long-QT syndrome); however, insight into the clinical phenotype is limited.
• Initial reports suggested that KCNE2 rare variants required additional stressors to manifest a clinical phenotype; however, current medical literature includes LQT6 as a canonical form of LQTS (long-QT syndrome).
WHAT THE STUDY ADDS
• Loss-of-function KCNE2 rare variants do not seem sufficient in isolation to cause LQTS, but may confer proarrhythmic susceptibility when provoked by additional environmental or genetic factors.
• Clinical management of individuals with loss-offunction KCNE2 variants and normal phenotypes should focus primarily on the avoidance of secondary stressors associated with QT prolongation. Do KCNE2 Mutations Cause LQTS? the KCNE2-Leu101Ter variant had normal QT behavior during treadmill testing and normal QTc values on serial surface ECGs (Table 1; Table III in the Data Supplement). The proband in family 21 had QTc values ranging from 430 to 465 ms and bidirectional ventricular tachycardia during exercise, while the proband in family 23 (Ser74Tyr) had recurrent polymorphic ventricular tachycardia triggered by short-coupled premature ventricular beats refractory to β-blockade, but responsive to quinidine. In family 24, the cause of aborted cardiac arrest in the proband has been attributed to arrhythmic mitral valve prolapse syndrome. 17 The remaining 4 probands (Families 18, 19, 20, and 22) had no arrhythmic phenotype, and all had their LQTS diagnoses removed by a specialized inherited arrhythmia clinic ( Table 1) .
None of the cases were reported to have clinically significant sinus node dysfunction or intolerance to β-blockade secondary to bradycardia. A single patient had transient complete atrioventricular block during cooling and ventricular preexcitation (Proband, family 5). Profound bradycardia complicated by TdP was observed in 3 probands (Families 5, 6, and 26) during systemic hypothermia initiated for neuroprotection after cardiac arrest.
Among the 28 reported families, excluding the 9 that possessed a pathogenic mutation in another LQTS gene, identification of a rare KCNE2 variant led to a diagnosis of LQT6 and initiation of β-blocker therapy by the initial treating team in 15 of the remaining 19 families. Cascade screening was performed in 8 of these 15 families, and 14 first-degree family members with normal phenotypes found to possess the KCNE2 variant were labeled with LQT6 and treated with a β-blocker. In family 14, the KCNE2 Met54Thr variant, and not the KCNH2 Arg148Trp mutation, was used for cascade screening of family members.
Literature Reported Cases
Among 36 index cases of LQTS attributed to KCNE2 mutations identified through the systematic literature review, 17 met prespecified inclusion criteria (Table 2) . One individual was a compound heterozygote (case 11-Ile20Asn and Arg27His), 20 while the Thr8Ala, Met54Thr, and Ile57Thr mutations were each present in 3 cases. [5] [6] [7] 19, 23 None of the reports provided evidence for familial genotype-phenotype segregation.
A secondary precipitant or additional genetic variant contributing to QT prolongation was documented in 10 cases (59%; Table 2 ). Eight had normal baseline QT intervals and only developed QT prolongation or TdP with a QT-prolonging medication (Table 2) . Of the 2 remaining, a baseline QT interval was not provided for case 8 (Arg77Trp), who developed TdP during complete atrioventricular block. 18 Case 10 (Phe60Ala) suffered an aborted arrest at 1 month of age, however, also possessed the well-established LQT3-causative mutation, SCN5A-Arg1623Gln (Table 2) . 19, 24 Case 14 (Thr10Met) suffered an aborted cardiac arrest in the context of hypokalemia and hypocalcemia, although had QTc prolongation at baseline (505 ms). 22 It is conceivable that her baseline QT interval prolongation was secondary to the Thr10Met mutation in isolation; however, 3 Thr10Met-positive family members had normal QT intervals, and patch-clamp analysis revealed only mild changes in I Kr when KCNE2-Thr10Met was coexpressed with wild-type KCNH2. 22 Of the 6 cases without a secondary precipitant (Table 2) , case 11, a 19-day-old infant that passed away secondary to recurrent episodes of ventricular fibrillation, was a compound heterozygote for Ile20Asn and Arg27His. 20 Although the QTc was 465 ms, her phenotype of recurrent ventricular fibrillation is atypical for LQTS (TdP not reported), although could have been a manifestation of her KCNE2 mutations. Case 12 had no evidence of QT prolongation (QTc=385 ms) and was diagnosed with LQT6 after identification of a KCNE2-Ile57Thr mutation as part of cascade screening for a family history of sudden cardiac death. 19 Case 13 was diagnosed with LQT6 in the context of syncope, a borderline QT interval (QTc=460 ms), and a novel KCNE2-Val65Met mutation. However, subsequent cascade screening revealed that this novel variant did not segregate with the QT prolongation observed in other family members. 21 The remaining 3 cases had phenotypes consistent with LQTS. A KCNE2-Met54Thr mutation was identified as the culprit in case 15 after an aborted arrest and a treadmill test that revealed QTc values ranging from 390 to 500 ms. 5 Case 16 (Met54Thr) was a 55-year-old asymptomatic male with a QTc =476 ms, 23 while case 17 (Arg77Trp) was a 67-year-old male with syncope and a QTc =514 ms. 19 In summary, of 44 probands possessing KCNE2 rare variants identified and reviewed in our study, only 7 (18%), including 4 of 17 (24%) from the literature (Table 2; Figure 2 ) and 3 of 27 (11%) in our novel case series (Table 1; Figure 2 ), had LQTS phenotypes in the absence of other genetic mutations or precipitating factors associated with QT prolongation. However, even in each of these cases, clinical and genetic findings suggested that the KCNE2 variant was not the underlying culprit.
Evaluation of KCNE2 Rare Variants
Population Allele Frequencies Among the 26 KCNE2 mutations reported as presumed or possibly pathogenic, 15 were in ExAC (Table 3; Figure 3 ). The allele frequencies for the 3 KCNE2 rare variants most often identified as culprits for LQT6, Thr8Ala (0.3804%), Met54Thr (0.0239%), and Ile57Thr (0.0881%) are much higher than anticipated for mutations causative for a rare autosomal dominant disorder. Allelic frequencies of the remaining KCNE2 mutations linked to LQT6 are provided in Table 3 . Current estimates suggest that the LQTS prevalence is ≈0.05%, while LQT6 is anticipated to account for 1% of LQTS, corresponding to a prevalence of 0.0005%. 26, 30, 31 Overall, 859 individuals within ExAC were positive for a KCNE2 variant previously implicated in LQT6 corresponding to an overall prevalence of 1.4%. This is 2800× the anticipated prevalence of LQT6.
Physicochemical and In Vitro Biophysical Analysis
In silico analysis of KCNE2 mutations implicated in LQT6 was performed using Polymorphism Phenotyping v2, Sorting Intolerant From Tolerant, and Mutation Taster ( In vitro biophysical analysis using patch clamping with heterologously expressed channels had been performed on 9 of 26 KCNE2 rare variants (Table 3 ). For 7 of the 9 variants, experimental findings were consistent with a loss-of-function, whereas functional work suggested that KCNE2-Arg27Cys resulted in a gain-of-function in I Ks , 29 and no electrophysiological changes in I Kr were observed for Arg77Trp. 18 Among the 7 loss-of-function mutations, the in vitro studies demonstrated a negligible reduction in potassium currents, in contrast to the severe and complete loss of function often observed with KCNQ1 and KCNH2 mutations implicated in LQT1 and LQT2, respectively. 5, 6, 18, 21, 22, 32, 33 
Discussion
Our investigation into the association between KCNE2 and LQTS has revealed that, when a KCNE2 variant was felt to be the primary culprit, the arrhythmic phenotype only manifested with a secondary stressor. We postulate that many KCNE2 variants, and perhaps all, have been designated erroneously as LQTScausative mutations. Instead, the small subset of functionally disruptive, pathogenic KCNE2 mutations seem to predispose to a phenotype more accurately reflective of an arrhythmiasusceptibility condition requiring secondary provocation, rather than a highly penetrant primary arrhythmic syndrome. This position is supported by the absence of a single reported family, either in the literature or our multicenter cohort, whereby a KCNE2 variant segregated with an LQTS phenotype and is further reinforced by the high allelic frequencies observed for reported culprit KCNE2 variants within ExAC.
Collectively, we think that our findings have important implications for the clinical management of patients with rare KCNE2 variants previously designated as LQT6-causative mutations. Unlike LQT1 and LQT2, patients with loss-offunction KCNE2 rare variants with a normal clinical and electrocardiographic phenotype should not be treated as concealed forms of LQTS. Instead, at most, they should be advised to avoid, when feasible, exposure to known QT-aggravating factors. Otherwise, 1.4% of the general population risks being labeled with a potentially lethal arrhythmia syndrome, treated with prophylactic β-blocker therapy, or worse, an implantable cardioverter-defibrillator, and restricted unnecessarily from sports. In other words, the majority of the KCNE2 variants published as LQT6-causative mutations need to be demoted to being at most variants of uncertain significance. 28, 34 The perceived value of cascade screening for these variants varies among investigators in this study, some advocating the benefit of education and knowledge for avoidance of QT-prolonging drugs, whereas others do not routinely use them to screen additional family members.
Within our study, 16 patients exclusively developed QT prolongation or TdP with a secondary stressor (Figure 2 ). Of cases that had phenotypes consistent with typical LQTS, 10 had pathogenic variants within other LQTS genes (Figure 2) . Given our findings, we suspect that these mutations were responsible for the LQTS phenotype, while the KCNE2 variants may have been modulators of arrhythmic risk or benign incidental findings. Eight of the index cases in our novel case series lacked an LQTS phenotype; however, identification of a KCNE2 variant often led to an LQTS diagnosis and overtreatment.
Seven cases from our study exhibited an LQTS phenotype in the presence of a KCNE2 mutation in isolation (Figure 2 ). Cases 15 and 16 from the literature (Table 2) possessed the Met54Thr mutation (ExAC allele frequency of 0.0239%). Although it is conceivable that Met54Thr may be contributing to their phenotype, its allele frequency in the general population is incompatible with a genetic culprit causative for a rare malignant arrhythmic syndrome. The same argument applies to the Ile57Thr-positive proband from family 27 (ExAC allele frequency: 0.0881%) whose first-degree family members also had normal QTc values (Table 1 ) and the Thr10Met-positive probands from family 26 and case 14 (ExAC allele frequency: 0.0182%). Case 17 (QT c =514 ms) from the literature (Table 2) possessed the Arg77Trp mutation (ExAC allele frequency: 0.0074%), previously shown to have no impact on I Kr . 18 The proband from family 28 (Glu94Gly; Table 1 ) had a QTc of 500 ms immediately after his subsequently fatal arrest. LQTS diagnoses in both of his children possessing the variant (QT c values ranging from 417 to 437 ms and 356 to 412 ms) were removed following the assessment in a specialized inherited arrhythmia clinic.
It should also be noted that studies have begun to implicate KCNE2 in nonarrhythmic conditions, including coronary artery disease, structural heart disease, and extracardiac disorders; however, our study was not designed to address these potential associations.
35,36
Limitations
The current report combines a novel multicenter experience with all previously reported cases with alleged LQT6 status. Despite this, we acknowledge that the number of cases and families is limited, and it is not possible to draw definitive conclusions about the phenotype associated with all KCNE2 variants. Meticulous evaluation of clinical phenotype remains paramount for ensuring delivery of optimal medical care. Clinical details were incomplete for multiple literature reported cases limiting inferences that could be drawn in those instances, while additional arrhythmic features, including sinus node dysfunction, preexcitation, and complete atrioventricular block, could not be systematically assessed in literature reported cases. Finally, the lack of evidence for genotype-phenotype segregation for KCNE2 may potentially be limited by the presence of relatively small families and an inability to perform larger-scale cascade screening. 
Conclusions
On the basis of the reported phenotypes of subjects with rare KCNE2 variants, coupled with the unacceptably high allelic frequencies of these variants within the general population, the findings from our study suggest that loss-of-function KCNE2 variants result in a phenotype more reflective of an arrhythmia-susceptibility condition requiring in the majority of cases secondary provocation by environmental or genetic factors, rather than representing a bona fide cause of monogenic LQTS. Clinical management of individuals with such loss-of-function KCNE2 variants with normal clinical/electrocardiographic phenotypes should focus primarily on the avoidance of secondary stressors associated with QT prolongation, rather than the more intensive interventions pursued with the canonical forms of LQTS.
